Cipla received USFDA approval for the first AB-rated generic of Ventolin HFA (albuterol inhaler), giving it a first-to-market edge with pharmacy-level substitution in the US. The broader market size ...

Indian pharmaceutical company Cipla has received final approval from the United States Food and Drug Administration (US FDA) to launch generic therapeutic equivalent of Ventolin, an albuterol inhaler.

Shares of Cipla Limited were trading lower on Friday morning, falling 1.27 per cent to ₹1,289.30 on the NSE by 10.12 AM, even as the pharmaceutical major announced a significant regulatory win in the ...

MUMBAI, India and WARREN, N.J., April 23, 2026 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA-EQ) (hereafter referred to as 'Cipla') and its wholly owned subsidiary Cipla USA Inc., (hereafter ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The drug treats and prevent bronchospasm in patients aged four years and above, including those with obstructive airway diseases, as well as for exercise-induced bronchospasm Shares of Cipla rose ...

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GSK plc (LSE/NYSE:GSK) announced Wednesday that its next-generation low carbon version of the Ventolin (salbutamol) metered dose inhaler (MDI) achieved positive results in pivotal phase III clinical ...

· If approved, this next-generation low carbon salbutamol has the potential to reduce greenhouse gas emissions by 92%3 per inhaler · GSK will proceed with regulatory submissions, with launch expected ...